Medistim

Report Publication Announcement • May 2, 2018

First presentation of the REQUEST study interim results

First presentation of the REQUEST study interim results

(Oslo, May 2nd, 2018) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the first presentation of interim results from the REQUEST registry study took place at the American Association of Thoracic Surgery (AATS) conference in San Diego yesterday.

The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and transit time flow measurement (TTFM) performed with Medistim's VeriQ C or MiraQ devices will change the surgical procedure. The REQUEST surgical coronary artery bypass grafting (CABG) protocol includes ultrasound scanning of the aorta, conduits, target coronary vessels and anastomoses, as well as TTFM graft assessment.

More than 1000 CABG patients were included in this prospective multicenter registry study

between April 2015 and December 2017. Seven leading cardiac surgery centers from Europe, USA and Canada, led by Coordinating Investigator Professor David Taggart from the University of Oxford, participated.

Yesterday, Dr. John D. Puskas, Chair of Cardiovascular Surgery at Mount Sinai St. Lukes hospital in New York, and one of the Principal Investigators in the REQUEST study, presented the results from an interim analysis of 961 patients at the AATS conference in San Diego.

The results showed that 26% of the patient population had one or more surgical changes made to the surgical strategy based on imaging and flow data. Of the sub-populations that went through aorta scanning and coronary target scanning, 10 % and 20 % of the patients had changes in the surgical strategy, respectively. Graft assessment with TTFM was performed in 99 % of the patients, with a result of 3 % anastomotic revision rate in 8 % of the patients. These results may be compared with previously published data showing about 3-5 % anastomotic revision rate in about 10 % of the patients. Furthermore, the in-hospital outcomes showed a remarkably low mortality rate of 0.5 % and stroke rate of 0.7 %.

"In the hands of expert cardiac surgeons, and using state-of-the-art surgical procedures, HFUS for surgical guidance and TTFM for graft assessment led to a 3 % revision rate of the anastomosis and very low level of in-hospital mortality and stroke rates", commented the Coordinating Investigator of the REQUEST study, Professor David Taggart. "One of the striking findings is that without routine assessment in the operating room most of these aorta and graft problems would have not been detected until after the patient had left the operating room. These results indicate that combining TTFM and HFUS in order to guide surgery, verify graft patency and to avoid or correct surgical problems intraoperatively may play an important role in our continued endeavors to improve CABG surgery and its outcomes to the benefit of our patients. It should therefore become a standard of care."

«Medistim's interest in this study has been to investigate and document the clinical value of the combined use of TTFM and HFUS", says Medistim President and CEO, Kari E. Krogstad. "With these results, we believe that the REQUEST study has provided new insights that may positively impact clinical outcomes and change clinical practice going forward. We are very much encouraged by the preliminary findings, and look forward to further analysis and results to become available from this vast patient material in order to continue learning and developing this surgical procedure."

About Medistim:

Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the US, Germany, Denmark, UK, Spain and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa and South America. For more information, visit the Medistim home page:

www.Medistim.com

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com

This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).